Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Deere & Company

Moderna

Healthpeak Properties

PepsiCo

Pfizer

Starbucks

AT&T

Verizon

WestRock

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Despite the COVID-19 pandemic, dividend income continues to grow, due primarily to additional investment and reinvestment. November through February 2021 proved to be pivotal moments for dividend investors, due to massive dividend increases.

Dividend Stock Purchase: Lanny's February 2021 Summary

The one-shot vaccine from Johnson & Johnson could be a game-changer, but perceptions that it is inferior must be actively dispelled

The Conversation: The backlash against Johnson & Johnson's COVID-19 vaccine is real and risky—here's exactly how to make its rollout a success

The latest approved vaccine candidate by Johnson & Johnson (NYSE: JNJ) for people over the age of 18 started shipping last week, shortly after receiving the Food and Drug Administration emergency use authorization. Approximately 4 million doses are to be distributed in the United States, with a total of 20 million by the end of the month.

Johnson And Johnson's Vaccine Could Be A Game Changer

A unanimous committee vote led to the quick authorization.

Here's What Investors Should Know About Johnson & Johnson's FDA Authorization

Broadcom

Annaly Capital

There's safety built into these income stocks if equities were to plunge.

The 4 Best Dividend Stocks to Buy If the Market Crashes

How the Johnson & Johnson vaccine news flooded the stock market with optimism.

Why the Johnson & Johnson Vaccine Is Big News

Johnson & Johnson (NYSE: JNJ) has told the European Union (EU) it is facing vaccine ingredients and equipment supply issues, probably impacting its plan to deliver 55 million doses of its COVID-19 vaccine to the bloc by the end of June, reports Reuters. What Happened: EU is already facing crunched supplies from other vaccine makers and a slow rollout of shots in many member states.

J&J Facing Supply Issues, Shaky To Meet EU Q2 Vaccine Deliveries: Reuters

Merck

iShares MSCI USA Momentum Factor ETF

SPDR Russell 1000 Momentum Focus ETF

Invesco DWA Momentum ETF

VictoryShares US Value Momentum ETF

Invesco S&P MidCap Momentum ETF

Here we highlight some momentum ETFs that are lucrative investment picks keeping in mind the optimism surrounding Wall Street.

Momentum ETFs to Gain From the New Stimulus Optimism

JNJ stock is a safe investment to add to your portfolio given its strong revenue growth potential and consistent dividend payout. The post Johnson & Johnson Is a Stock to Buy and Hold Forever appeared first on InvestorPlace.

Johnson & Johnson Is a Stock to Buy and Hold Forever

Costco

Amid rising bond yields, an aggressive stimulus package, and a pandemic, Q.ai's deep learning algorithms have found you this week's top trending stocks.

Costco And Johnson & Johnson Among Trending Stocks This Week

U.S. President Biden will meet with the chief executives of Johnson & Johnson and Merck & Co Inc at the White House on Wednesday after the companies recently announced a COVID-19 vaccine manufacturing deal, a White House official said on Monday.

Biden to meet on with CEOs of JNJ, Merck at White House on Wednesday: official

It has to do with when the pandemic ends.

When Will Johnson & Johnson Post a Profit from its COVID Vaccine?

American Express

Cisco Systems

Disney

Intel

Jounce Therapeutics

JPMorgan Chase & Co

UnitedHealth Group

Two new breakout stocks for Week 10 of 2021 with better than 10% short-term upside potential. This past week both LMAT +12.5% and YI +12.2% gained more than 10% while the average return to the close for all four tech/healthcare selections was a loss of -22.9%.

Week 10 MDA Breakout Stocks - March 2021: Short-Term Picks To Give You An Edge

AstraZeneca

BioNTech SE

CureVac B.V

Novavax

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt.

Vaccine Miracles: Does JNJ Kill the Profit Path for MRNA and NVAX?

FedEx

PayPal

The fourth quarter ended Dec. 31 marked the third consecutive quarter of the latest bull run for U.S. stock markets, with the major indexes reaching new unprecedented highs. The S&P 500 surpassed 3,700 for the first time in history during this period, the Nasdaq rocketed above 12,800 and the Dow Jones Industrial Average surpassed its pre-Covid highs.

The 5 Most-Sold Guru Stocks of the 4th Quarter

Apple

Microsoft

Peloton

Alphabet

Home Depot

The remote economy has served as a tailwind for numerous mega-cap stocks that show a lot of future growth potential. Here are 7 stocks worth buying this year.

7 Mega-Cap Stocks Standing Above the Fray

Shares of Johnson & Johnson gained 1.4% in trading on Friday after Canada's health regulatory body said it authorized the company's COVID-19 vaccine. The single-dose vaccine received emergency use authorization in the U.S. on Saturday.

Canada authorizes J&J's COVID-19 vaccine

DuPont de Nemours

Welcome to FOMO — the Fear of Missing Out, cautions Chuck Carlson, a leading expert on dividend reinvestment plans, the editor of DRIP Investor and a contributor to MoneyShow.com.

3M, DuPont And J&J: A Fresh Take On 3 Old-Time Names

Abbott Labs

These four MedTech stocks -- ABT, JNJ, MDT and MASI -- are expected to gain enormously from FDA's SaMD Action Plan 2021.

News for Johnson & Johnson Stock (JNJ)